AstraZeneca announced positive late-stage trial results for a two-drug combination treating a resistant form of lung cancer. The combo pairs Tagrisso, an established lung cancer pill, with Orpathys, a newer drug targeting the MET protein that causes resistance. Patients on both drugs lived longer and delayed disease progression compared to standard chemotherapy. The all-oral treatment, already approved in China, may soon gain global approval, providing a new option for patients facing limited treatments.
Jefferies has maintained a 'buy' rating on AstraZeneca with a price target of 17,500p, implying a 46% upside from the current share price. The broker expects AstraZeneca's third-quarter revenue to exceed consensus by about 1%, and core earnings befor...
Citigroup has raised its price target for AstraZeneca to £186.00 from £178.00, maintaining a Buy rating following successful Phase 3 clinical trials. The increase reflects higher peak sales forecasts for drugs tozorakimab and SERENA-6, offsetting the...
Citi has increased its target price for AstraZeneca to £186 from £178, maintaining a 'buy' rating after positive clinical developments, especially for the drug tozorakimab. The broker raised peak sales forecasts for tozorakimab to $7 billion and SERE...
AstraZeneca announced a $2 billion equity investment and clinical collaboration with Summit Therapeutics to develop ivonescimab, a first-in-class bispecific antibody for cancer treatment. This drug targets two cancer pathways simultaneously, potentia...
